Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077130 | 0.90 | SIGMAR1 (0.49) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL30767848 | 0.89 | KMT2A (0.53) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL322777 | 0.89 | KMT2A (0.53) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL2532723 | 0.87 | SIGMAR1 (0.43) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL4079977 | 0.84 | LIMK1 (0.49) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL14111444 | 0.84 | LIMK1 (0.49) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL4982960 | 0.84 | LIMK1 (0.61) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL12386805 | 0.83 | P2RX7 (0.50) | KMT2AKDM4EALDH1A1GLAGAA | |
| Hydrochloric Acid SCHEMBL4982981 | 0.83 | LIMK1 (0.48) | KMT2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL5772203 | 0.81 | LIMK1 (0.46) | KMT2AKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118480029-A | 2-Aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-115677729-A | AAK1 inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| CN-108431001-B | Fused ring pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-09-17 | — | — | CN | disclosed |
| EP-3381916-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-15 | — | — | EP | disclosed |
| US-10370372-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-08-06 | — | — | US | disclosed |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180312505-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| EP-3150599-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-10-24 | — | — | EP | disclosed |
| EP-3381916-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
| EP-1363899-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030191143-A1 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20030092908-A1 | Fused heterocyclic inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002087513-A2 | FUSED HETEROCYCLIC INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002053558-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMAN-LA ROCHE AG (CH) | 2002-07-11 | — | — | WO | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | KMT2A 3518/4885KDM4E 3553/4885ALDH1A1 875/4885 |
| US-20030092908-A1 | Fused heterocyclic inhibitors of phosphodiesterase (PDE) 7 | PDE3A, PDE5A, PDE3B | KMT2A 1054/4885KDM4E 495/4885ALDH1A1 806/4885 |
| US-20180312505-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | AR, NR5A1, FSHR | KMT2A 1117/4885KDM4E 2033/4885ALDH1A1 1909/4885 |
| US-10300067-B2 | Tetrahydropyridopyrimidine compound or salt thereof | NR5A1, CYP17A1, DPYD | KMT2A 1083/4885KDM4E 2393/4885ALDH1A1 309/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | KMT2A 2003/4885KDM4E 2989/4885ALDH1A1 514/4885 |
| US-20030191143-A1 | Fused heterocyclic compounds and use thereof | NFATC1, MCL1, BCR | KMT2A 1178/4885KDM4E 2667/4885ALDH1A1 380/4885 |
| US-10370372-B2 | Fused pyrimidine compound or salt thereof | AR, NR5A1, FSHR | KMT2A 1117/4885KDM4E 2033/4885ALDH1A1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.